Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril

Montreal Heart Institute, Quebec, Canada.

OBJECTIVES. This study attempted to evaluate whether neurohumoral activation at the time of hospital discharge in postinfarction patients helps to predict long-term prognosis and whether long-term therapy with the angiotensin-converting enzyme inhibitor captopril modifies this relation. BACKGROUND. Neurohumoral activation persists at the time of hospital discharge in a large number of postinfarction patients. The Survival and Ventricular Enlargement (SAVE) study demonstrated that the angiotensin-converting enzyme inhibitor captopril improves survival and decreases the development of severe heart failure in patients with left ventricular dysfunction (left ventricular ejection fraction < or = 40%) but no overt postinfarction heart failure. METHODS. In 534 patients in the SAVE study, plasma neurohormone levels were measured a mean of 12 days after infarction. Patients were then randomized to receive captopril or placebo and were followed up for a mean (+/- SD) of 38 +/- 6 months (range 24 to 55). The association between activation of plasma neurohormones at baseline and subsequent cardiovascular mortality or the development of heart failure was assessed with and without adjustment for other important prognostic factors. RESULTS. By univariate analysis, activation of plasma renin activity and aldosterone, norepinephrine, atrial natriuretic peptide and arginine vasopressin levels were related to subsequent cardiovascular events, whereas epinephrine and dopamine levels were not. By multivariate analysis, only plasma renin activity (relative risk 1.6, 95% confidence interval [CI] 1.0 to 2.5) and atrial natriuretic peptide (relative risk 2.2, 95% CI 1.3 to 3.8) were independently predictive of cardiovascular mortality, whereas the other neurohormones were not. Only plasma renin activity and aldosterone, atrial natriuretic peptide and arginine vasopressin were independent predictors of the combined end points of cardiovascular mortality, development of severe heart failure or recurrent myocardial infarction. Except for 1-year cardiovascular mortality, the use of captopril did not significantly modify these relations. CONCLUSIONS. Neurohumoral activation at the time of hospital discharge in postinfarction patients is an independent sign of poor prognosis. This is particularly true for plasma renin activity and atrial natriuretic peptide. Except for 1-year cardiovascular mortality, captopril does not significantly modify these relations.

This article has been cited by other articles:

				S. Neuhold, M. Huelsmann, G. Strunk, B. Stoiser, J. Struck, N. G. Morgenthaler, A. Bergmann, D. Moertl, R. Berger, and R. Pacher Comparison of Copeptin, B-Type Natriuretic Peptide, and Amino-Terminal Pro-B-Type Natriuretic Peptide in Patients With Chronic Heart Failure: Prediction of Death at Different Stages of the Disease J. Am. Coll. Cardiol., July 22, 2008; 52(4): 266 - 272. [Abstract] [Full Text] [PDF]

				J. Gutkowska, M. Miszkurka, B. Danalache, N. Gassanov, D. Wang, and M. Jankowski Functional arginine vasopressin system in early heart maturation Am J Physiol Heart Circ Physiol, October 1, 2007; 293(4): H2262 - H2270. [Abstract] [Full Text] [PDF]

				J. E. Udelson, F. A. McGrew, E. Flores, H. Ibrahim, S. Katz, G. Koshkarian, T. O'Brien, M. W. Kronenberg, C. Zimmer, C. Orlandi, et al. Multicenter, Randomized, Double-Blind, Placebo-Controlled Study on the Effect of Oral Tolvaptan on Left Ventricular Dilation and Function in Patients With Heart Failure and Systolic Dysfunction J. Am. Coll. Cardiol., June 5, 2007; 49(22): 2151 - 2159. [Abstract] [Full Text] [PDF]

				D. Aronson, H. Hammerman, M. R. Kapeliovich, A. Suleiman, Y. Agmon, R. Beyar, W. Markiewicz, and M. Suleiman Fasting Glucose in Acute Myocardial Infarction: Incremental value for long-term mortality and relationship with left ventricular systolic function Diabetes Care, April 1, 2007; 30(4): 960 - 966. [Abstract] [Full Text] [PDF]

				E. M. deGoma, R. H. Vagelos, M. B. Fowler, and E. A. Ashley Emerging Therapies for the Management of Decompensated Heart Failure: From Bench to Bedside J. Am. Coll. Cardiol., December 19, 2006; 48(12): 2397 - 2409. [Abstract] [Full Text] [PDF]

				F. Beygui, J.-P. Collet, J.-J. Benoliel, N. Vignolles, R. Dumaine, O. Barthelemy, and G. Montalescot High Plasma Aldosterone Levels on Admission Are Associated With Death in Patients Presenting With Acute ST-Elevation Myocardial Infarction Circulation, December 12, 2006; 114(24): 2604 - 2610. [Abstract] [Full Text] [PDF]

				S. J. Buss, J. Backs, M. M. Kreusser, S. E. Hardt, C. Maser-Gluth, H. A. Katus, and M. Haass Spironolactone Preserves Cardiac Norepinephrine Reuptake in Salt-Sensitive Dahl Rats Endocrinology, May 1, 2006; 147(5): 2526 - 2534. [Abstract] [Full Text] [PDF]

				A. Goldberg, H. Hammerman, S. Petcherski, M. Nassar, A. Zdorovyak, S. Yalonetsky, M. Kapeliovich, Y. Agmon, R. Beyar, W. Markiewicz, et al. Hyponatremia and Long-term Mortality in Survivors of Acute ST-Elevation Myocardial Infarction. Arch Intern Med, April 10, 2006; 166(7): 781 - 786. [Abstract] [Full Text] [PDF]

				P. P Liu, A. Maggioni, and E. J Velazquez Use of Valsartan in Post-Myocardial Infarction and Heart Failure Patients Journal of Renin-Angiotensin-Aldosterone System, March 1, 2006; 7(1_suppl): S19 - S22. [Abstract] [PDF]

				S. R. Goldsmith and M. Gheorghiade Vasopressin Antagonism in Heart Failure J. Am. Coll. Cardiol., November 15, 2005; 46(10): 1785 - 1791. [Abstract] [Full Text] [PDF]

				D. Fraccarollo, P. Galuppo, I. Schmidt, G. Ertl, and J. Bauersachs Additive amelioration of left ventricular remodeling and molecular alterations by combined aldosterone and angiotensin receptor blockade after myocardial infarction Cardiovasc Res, July 1, 2005; 67(1): 97 - 105. [Abstract] [Full Text] [PDF]

				M U Braun, T Rauwolf, T Zerm, M Schulze, A Schnabel, and R H Strasser Long term biventricular resynchronisation therapy in advanced heart failure: effect on neurohormones Heart, May 1, 2005; 91(5): 601 - 605. [Abstract] [Full Text] [PDF]

				P. Sanghi, B. F. Uretsky, and E. R. Schwarz Vasopressin antagonism: a future treatment option in heart failure Eur. Heart J., March 2, 2005; 26(6): 538 - 543. [Abstract] [Full Text] [PDF]

				A. D Struthers and T. M MacDonald Review of aldosterone- and angiotensin II-induced target organ damage and prevention Cardiovasc Res, March 1, 2004; 61(4): 663 - 670. [Abstract] [Full Text] [PDF]

				R. Latini, S. Masson, I. Anand, M. Salio, A. Hester, D. Judd, S. Barlera, A. P Maggioni, G. Tognoni, J. N Cohn, et al. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT Eur. Heart J., February 2, 2004; 25(4): 292 - 299. [Abstract] [Full Text] [PDF]

				D. Fraccarollo, P. Galuppo, S. Hildemann, M. Christ, G. Ertl, and J. Bauersachs Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction J. Am. Coll. Cardiol., November 5, 2003; 42(9): 1666 - 1673. [Abstract] [Full Text] [PDF]

				A. M. Richards, M. G. Nicholls, E. A. Espiner, J. G. Lainchbury, R. W. Troughton, J. Elliott, C. Frampton, J. Turner, I. G. Crozier, and T. G. Yandle B-Type Natriuretic Peptides and Ejection Fraction for Prognosis After Myocardial Infarction Circulation, June 10, 2003; 107(22): 2786 - 2792. [Abstract] [Full Text] [PDF]

				H. Ruskoaho Cardiac Hormones as Diagnostic Tools in Heart Failure Endocr. Rev., June 1, 2003; 24(3): 341 - 356. [Abstract] [Full Text] [PDF]

				M. Hayashi, T. Tsutamoto, A. Wada, T. Tsutsui, C. Ishii, K. Ohno, M. Fujii, A. Taniguchi, T. Hamatani, Y. Nozato, et al. Immediate Administration of Mineralocorticoid Receptor Antagonist Spironolactone Prevents Post-Infarct Left Ventricular Remodeling Associated With Suppression of a Marker of Myocardial Collagen Synthesis in Patients With First Anterior Acute Myocardial Infarction Circulation, May 27, 2003; 107(20): 2559 - 2565. [Abstract] [Full Text] [PDF]

				M. F. Rousseau, O. Gurne, D. Duprez, W. Van Mieghem, A. Robert, S. Ahn, L. Galanti, J.-M. Ketelslegers, and Belgian RALES Investigators Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: Results from the RALES neurohormonal substudy J. Am. Coll. Cardiol., November 6, 2002; 40(9): 1596 - 1601. [Abstract] [Full Text] [PDF]

				S. R. Goldsmith Vasopressin antagonists in CHF: ready for clinical trials? Cardiovasc Res, April 1, 2002; 54(1): 13 - 15. [Full Text] [PDF]

				C. Zoccali, F. Mallamaci, S. Parlongo, S. Cutrupi, F. A. Benedetto, G. Tripepi, G. Bonanno, F. Rapisarda, P. Fatuzzo, G. Seminara, et al. Plasma Norepinephrine Predicts Survival and Incident Cardiovascular Events in Patients With End-Stage Renal Disease Circulation, March 19, 2002; 105(11): 1354 - 1359. [Abstract] [Full Text] [PDF]

				J. E. Udelson, W. B. Smith, G. H. Hendrix, C. A. Painchaud, M. Ghazzi, I. Thomas, J. K. Ghali, P. Selaru, F. Chanoine, M. L. Pressler, et al. Acute Hemodynamic Effects of Conivaptan, a Dual V1A and V2 Vasopressin Receptor Antagonist, in Patients With Advanced Heart Failure Circulation, November 13, 2001; 104(20): 2417 - 2423. [Abstract] [Full Text] [PDF]

				M. Hayashi, T. Tsutamoto, A. Wada, K. Maeda, N. Mabuchi, T. Tsutsui, T. Matsui, M. Fujii, T. Matsumoto, T. Yamamoto, et al. Relationship between transcardiac extraction of aldosterone and left ventricular remodeling in patients with first acute myocardial infarction: extracting aldosterone through the heart promotes ventricular remodeling after acute myocardial infarction J. Am. Coll. Cardiol., November 1, 2001; 38(5): 1375 - 1382. [Abstract] [Full Text] [PDF]

				G Berton, R Cordiano, R Palmieri, F Cucchini, R de Toni, and P Palatini Microalbuminuria during acute myocardial infarction; a strong predictor for 1-year mortality Eur. Heart J., August 2, 2001; 22(16): 1466 - 1475. [Abstract] [PDF]

				A. M. Richards, R. Doughty, M. G. Nicholls, S. MacMahon, N. Sharpe, J. Murphy, E. A. Espiner, C. Frampton, T. G. Yandle, and for the Australia-New Zealand Heart Failure Group Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: Prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction J. Am. Coll. Cardiol., June 1, 2001; 37(7): 1781 - 1787. [Abstract] [Full Text] [PDF]

				D. B. Reuben, S. L.A. Talvi, J. W. Rowe, and T. E. Seeman High Urinary Catecholamine Excretion Predicts Mortality and Functional Decline in High-Functioning, Community-Dwelling Older Persons: MacArthur Studies of Successful Aging J. Gerontol. A Biol. Sci. Med. Sci., October 1, 2000; 55(10): 618M - 624. [Abstract] [Full Text]

				S. D. Kim and M. R. Piano The Natriuretic Peptides: Physiology and Role in Left-Ventricular Dysfunction Biol Res Nurs, July 1, 2000; 2(1): 15 - 29. [Abstract] [PDF]

				C Berry and A.L Clark Catabolism in chronic heart failure Eur. Heart J., April 1, 2000; 21(7): 521 - 532. [PDF]

				T. Tsutamoto, A. Wada, K. Maeda, N. Mabuchi, M. Hayashi, T. Tsutsui, M. Ohnishi, M. Sawaki, M. Fujii, T. Matsumoto, et al. Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure J. Am. Coll. Cardiol., March 1, 2000; 35(3): 714 - 721. [Abstract] [Full Text] [PDF]

				C. Hengstenberg, S. R. Holmer, B. Mayer, H. Lowel, S. Engel, H.-W. Hense, G. A. J. Riegger, and H. Schunkert Evaluation of the Aldosterone Synthase (CYP11B2) Gene Polymorphism in Patients With Myocardial Infarction Hypertension, March 1, 2000; 35(3): 704 - 709. [Abstract] [Full Text] [PDF]

				S. D. Kim Measurement of the Renin-Angiotensin System in Heart Failure Biol Res Nurs, January 1, 2000; 1(3): 210 - 226. [Abstract] [PDF]

				T. Tsutamoto, A. Wada, K. Maeda, T. Hisanaga, N. Mabuchi, M. Hayashi, M. Ohnishi, M. Sawaki, M. Fujii, H. Horie, et al. Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction. Comparison with plasma angiotensin II and endothelin-1 Eur. Heart J., December 2, 1999; 20(24): 1799 - 1807. [Abstract] [PDF]

				X.-L. Qi, D. J. Stewart, H. Gosselin, A. Azad, P. Picard, L. Andries, S. U. Sys, D. L. Brutsaert, and J. L. Rouleau Improvement of Endocardial and Vascular Endothelial Function on Myocardial Performance by Captopril Treatment in Postinfarct Rat Hearts Circulation, September 21, 1999; 100(12): 1338 - 1345. [Abstract] [Full Text] [PDF]

				A. T. Hirsch, J. A. Opsahl, M. M. Lunzer, and S. A. Katz Active renin and angiotensinogen in cardiac interstitial fluid after myocardial infarction Am J Physiol Heart Circ Physiol, June 1, 1999; 276(6): H1818 - H1826. [Abstract] [Full Text] [PDF]

				A. M. Richards, R. Doughty, M. G. Nicholls, S. Macmahon, H. Ikram, N. Sharpe, E. A. Espiner, C. Frampton, and T. G. Yandle Neurohumoral Prediction of Benefit From Carvedilol in Ischemic Left Ventricular Dysfunction Circulation, February 16, 1999; 99(6): 786 - 792. [Abstract] [Full Text] [PDF]

				G. Berton, T. Citro, R. Palmieri, S. Petucco, S. Renzo De Toni, and P. Palatini Albumin Excretion Rate Increases During Acute Myocardial Infarction and Strongly Predicts Early Mortality Circulation, November 18, 1997; 96(10): 3338 - 3345. [Abstract] [Full Text]

				T. Shimosawa, K. Ando, and T. Fujita A Newly Identified Peptide, Proadrenomedullin N-Terminal 20 Peptide, Induces Hypotensive Action via Pertussis Toxin–Sensitive Mechanisms Hypertension, November 1, 1997; 30(5): 1009 - 1014. [Abstract] [Full Text]

				T. Tsutamoto, A. Wada, K. Maeda, T. Hisanaga, Y. Maeda, D. Fukai, M. Ohnishi, Y. Sugimoto, and M. Kinoshita Attenuation of Compensation of Endogenous Cardiac Natriuretic Peptide System in Chronic Heart Failure : Prognostic Role of Plasma Brain Natriuretic Peptide Concentration in Patients With Chronic Symptomatic Left Ventricular Dysfunction Circulation, July 15, 1997; 96(2): 509 - 516. [Abstract] [Full Text]

				C. R. Benedict, B. Shelton, D. E. Johnstone, G. Francis, B. Greenberg, M. Konstam, J. L. Probstfield, and S. Yusuf Prognostic Significance of Plasma Norepinephrine in Patients With Asymptomatic Left Ventricular Dysfunction Circulation, August 15, 1996; 94(4): 690 - 697. [Abstract] [Full Text]

				R. O. Bonow New Insights Into the Cardiac Natriuretic Peptides Circulation, June 1, 1996; 93(11): 1946 - 1950. [Full Text]

				T. Omland, A. Aakvaag, V. V. S. Bonarjee, K. Caidahl, R. T. Lie, D. W. T. Nilsen, J. A. Sundsfjord, and K. Dickstein Plasma Brain Natriuretic Peptide as an Indicator of Left Ventricular Systolic Function and Long-term Survival After Acute Myocardial Infarction : Comparison With Plasma Atrial Natriuretic Peptide and N-Terminal Proatrial Natriuretic Peptide Circulation, June 1, 1996; 93(11): 1963 - 1969. [Abstract] [Full Text]